Review



c myc plasmid  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Addgene inc c myc plasmid
    C Myc Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 79 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plasmid+16011/pcDNA3-cmyc+(Plasmid+%2316011)/10__3390_slash_microorganisms14102368-108-9-11
    Average 93 stars, based on 79 article reviews
    c myc plasmid - by Bioz Stars, 2026-11
    93/100 stars

    Images

    Related Articles

    other:

    Article Title: Zipcode Binding Protein 1 Regulates the Development of Dendritic Arbors in Hippocampal Neurons
    Article Snippet: The following DNA constructs have been previously described: pEGFP-rZBP1 ( Eom et al., 2003 ), pStau1-EYFP, pStau2-EYFP, pSuperior-Stau2sh ( Goetze et al., 2006 ), β-actin-GFP ( Jaworski et al., 2005 ), β-actin-mRFP, FLAG-CaMKIIα ( Hoogenraad et al., 2007 ), β-actin-mCherry ( de Vrij et al., 2008 ), pSuper ( Brummelkamp et al., 2002 ), and pPDGF-EGFP-β-actin ( Morales et al., 2000 ). pcDNA3-c-Myc ( Ricci et al., 2004 ) and pExpress-1-α-actin were acquired from Addgene (plasmid 16011) and ImaGenes (clone IRBPp993E0552D), respectively.

    Over Expression:

    Article Title: Carcinoma diagnosis and treatment based on ODC1 genotype
    Article Snippet: The Renilla-TK plasmid was purchased from Promega and used as a transfection efficiency control in all promoter-reporter transfection experiments. .. For the overexpression experiments, ODC1 pGL3-Basic or Enhancer plasmids were co-transfected with the corresponding plasmid: pcDNA 3.0 empty vector, pcDNA3-c-MYC expression vector (Ricci et al., 2004) (Addgene plasmid 16011), full-length pN3-Sp1FL (Sapetschnig et al., 2004) (Addgene plasmid 24543), pN3-empty control (Addgene plasmid 24544), N-terminal mutate pPac-Sp1 (Courey and Tjian, 1988) (Addgene plasmid 12095) and pPac0 empty vector (Courey and Tjian, 1988) (Addgene plasmid 12094). ..

    Article Title: Carcinoma diagnosis and treatment based on ODC1 genotype
    Article Snippet: .. For c-MYC and Sp1 overexpression experiments, ODC1 pGL3-Basic plasmids were co-transfected with either pcDNA 3.0 (vector control) or pcDNA3-c-MYC expression vector (Ricci et al., 2004) (Addgene plasmid 16011) and pN3-empty vector control (Addgene plasmid 24544) or full-length Sp1FL (Addgene plasmid 24543) (Sapetschnig et al., 2004). ..

    Plasmid Preparation:

    Article Title: Carcinoma diagnosis and treatment based on ODC1 genotype
    Article Snippet: The Renilla-TK plasmid was purchased from Promega and used as a transfection efficiency control in all promoter-reporter transfection experiments. .. For the overexpression experiments, ODC1 pGL3-Basic or Enhancer plasmids were co-transfected with the corresponding plasmid: pcDNA 3.0 empty vector, pcDNA3-c-MYC expression vector (Ricci et al., 2004) (Addgene plasmid 16011), full-length pN3-Sp1FL (Sapetschnig et al., 2004) (Addgene plasmid 24543), pN3-empty control (Addgene plasmid 24544), N-terminal mutate pPac-Sp1 (Courey and Tjian, 1988) (Addgene plasmid 12095) and pPac0 empty vector (Courey and Tjian, 1988) (Addgene plasmid 12094). ..

    Article Title: Carcinoma diagnosis and treatment based on ODC1 genotype
    Article Snippet: .. For c-MYC and Sp1 overexpression experiments, ODC1 pGL3-Basic plasmids were co-transfected with either pcDNA 3.0 (vector control) or pcDNA3-c-MYC expression vector (Ricci et al., 2004) (Addgene plasmid 16011) and pN3-empty vector control (Addgene plasmid 24544) or full-length Sp1FL (Addgene plasmid 24543) (Sapetschnig et al., 2004). ..

    Expressing:

    Article Title: Carcinoma diagnosis and treatment based on ODC1 genotype
    Article Snippet: The Renilla-TK plasmid was purchased from Promega and used as a transfection efficiency control in all promoter-reporter transfection experiments. .. For the overexpression experiments, ODC1 pGL3-Basic or Enhancer plasmids were co-transfected with the corresponding plasmid: pcDNA 3.0 empty vector, pcDNA3-c-MYC expression vector (Ricci et al., 2004) (Addgene plasmid 16011), full-length pN3-Sp1FL (Sapetschnig et al., 2004) (Addgene plasmid 24543), pN3-empty control (Addgene plasmid 24544), N-terminal mutate pPac-Sp1 (Courey and Tjian, 1988) (Addgene plasmid 12095) and pPac0 empty vector (Courey and Tjian, 1988) (Addgene plasmid 12094). ..

    Article Title: Carcinoma diagnosis and treatment based on ODC1 genotype
    Article Snippet: .. For c-MYC and Sp1 overexpression experiments, ODC1 pGL3-Basic plasmids were co-transfected with either pcDNA 3.0 (vector control) or pcDNA3-c-MYC expression vector (Ricci et al., 2004) (Addgene plasmid 16011) and pN3-empty vector control (Addgene plasmid 24544) or full-length Sp1FL (Addgene plasmid 24543) (Sapetschnig et al., 2004). ..

    Control:

    Article Title: Carcinoma diagnosis and treatment based on ODC1 genotype
    Article Snippet: The Renilla-TK plasmid was purchased from Promega and used as a transfection efficiency control in all promoter-reporter transfection experiments. .. For the overexpression experiments, ODC1 pGL3-Basic or Enhancer plasmids were co-transfected with the corresponding plasmid: pcDNA 3.0 empty vector, pcDNA3-c-MYC expression vector (Ricci et al., 2004) (Addgene plasmid 16011), full-length pN3-Sp1FL (Sapetschnig et al., 2004) (Addgene plasmid 24543), pN3-empty control (Addgene plasmid 24544), N-terminal mutate pPac-Sp1 (Courey and Tjian, 1988) (Addgene plasmid 12095) and pPac0 empty vector (Courey and Tjian, 1988) (Addgene plasmid 12094). ..

    Article Title: Carcinoma diagnosis and treatment based on ODC1 genotype
    Article Snippet: .. For c-MYC and Sp1 overexpression experiments, ODC1 pGL3-Basic plasmids were co-transfected with either pcDNA 3.0 (vector control) or pcDNA3-c-MYC expression vector (Ricci et al., 2004) (Addgene plasmid 16011) and pN3-empty vector control (Addgene plasmid 24544) or full-length Sp1FL (Addgene plasmid 24543) (Sapetschnig et al., 2004). ..



    Similar Products

    93
    Addgene inc c myc plasmid
    C Myc Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plasmid+16011/pcDNA3-cmyc+(Plasmid+%2316011)/10__3390_slash_microorganisms14102368-108-9-11
    Average 93 stars, based on 1 article reviews
    c myc plasmid - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    93
    Addgene inc pgenlenti flag mda5
    Pgenlenti Flag Mda5, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plasmid+16011/pcDNA3-cmyc+(Plasmid+%2316011)/pm41022715-305-10-23
    Average 93 stars, based on 1 article reviews
    pgenlenti flag mda5 - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    93
    Addgene inc human pcdna3 c myc plasmid
    Human Pcdna3 C Myc Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plasmid+16011/pcDNA3-cmyc+(Plasmid+%2316011)/pmc12209437-430-10-14
    Average 93 stars, based on 1 article reviews
    human pcdna3 c myc plasmid - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    93
    Addgene inc pcdna3 myc plasmid
    Pcdna3 Myc Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plasmid+16011/pcDNA3-cmyc+(Plasmid+%2316011)/pmc12168343-130-5-7
    Average 93 stars, based on 1 article reviews
    pcdna3 myc plasmid - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    93
    Addgene inc wt yap
    Wt Yap, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plasmid+16011/pcDNA3-cmyc+(Plasmid+%2316011)/pm40484249-259-16-22
    Average 93 stars, based on 1 article reviews
    wt yap - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    93
    Addgene inc myc overexpressing h460 cells pcdna3 cmyc
    Figure 3. Cell-cycle arrest and apoptosis induced by the combination treatment (A and B) Flow cytometry analysis of EdU (5-ethynyl-2’-deoxyuridine) and DNA staining. <t>H460</t> and H1703 cells were treated with vehicle, MYCi975 (5 μM), TMP195 (25 μM), or both for 48 h, then incubated with EdU for 2 h and stained for EdU and FxCycle Violet. Representative flow cytometry dot plots illustrating the gating strategy (A). A, G0/G1; B, S; C, G2/M. Percentages of cells in G0/G1, S, or G2/M phase are presented as mean ± SD (B). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 calculated using one-way ANOVA followed by Tukey’s multiple comparisons test. n = 3 biological replicates. (C) Flow cytometry analysis of phosphatidylinositol (PI) and Annexin V staining. H460 and H1703 cells were treated with vehicle, MYCi975 (5 μM), TMP195 (25 μM), or both for 72 h. Representative flow cytometry dot plots illustrating the gating strategy. A, necrotic; B, late apoptotic; C, early apoptotic. (D) Percentages of cells in necrotic, late-apoptotic, or early-apoptotic status treated with vehicle, MYCi975 (5 μM), TMP195 (25 μM), or both for 24, 48, and 72 h are presented as mean ± SD. n = 3 biological replicates. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 calculated for necrotic + apoptotic cell percentages for each condition using one-way ANOVA followed by Tukey’s multiple comparisons test. V, vehicle; M, MYCi975; T, TMP195; C, combo (B and D).
    Myc Overexpressing H460 Cells Pcdna3 Cmyc, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plasmid+16011/pcDNA3-cmyc+(Plasmid+%2316011)/pm40392656-264-4-9
    Average 93 stars, based on 1 article reviews
    myc overexpressing h460 cells pcdna3 cmyc - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    93
    Addgene inc recombinant dna pcdna3 cmyc addgene addgene
    Figure 3. Cell-cycle arrest and apoptosis induced by the combination treatment (A and B) Flow cytometry analysis of EdU (5-ethynyl-2’-deoxyuridine) and DNA staining. <t>H460</t> and H1703 cells were treated with vehicle, MYCi975 (5 μM), TMP195 (25 μM), or both for 48 h, then incubated with EdU for 2 h and stained for EdU and FxCycle Violet. Representative flow cytometry dot plots illustrating the gating strategy (A). A, G0/G1; B, S; C, G2/M. Percentages of cells in G0/G1, S, or G2/M phase are presented as mean ± SD (B). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 calculated using one-way ANOVA followed by Tukey’s multiple comparisons test. n = 3 biological replicates. (C) Flow cytometry analysis of phosphatidylinositol (PI) and Annexin V staining. H460 and H1703 cells were treated with vehicle, MYCi975 (5 μM), TMP195 (25 μM), or both for 72 h. Representative flow cytometry dot plots illustrating the gating strategy. A, necrotic; B, late apoptotic; C, early apoptotic. (D) Percentages of cells in necrotic, late-apoptotic, or early-apoptotic status treated with vehicle, MYCi975 (5 μM), TMP195 (25 μM), or both for 24, 48, and 72 h are presented as mean ± SD. n = 3 biological replicates. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 calculated for necrotic + apoptotic cell percentages for each condition using one-way ANOVA followed by Tukey’s multiple comparisons test. V, vehicle; M, MYCi975; T, TMP195; C, combo (B and D).
    Recombinant Dna Pcdna3 Cmyc Addgene Addgene, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plasmid+16011/pcDNA3-cmyc+(Plasmid+%2316011)/pm40392656-199-201-204
    Average 93 stars, based on 1 article reviews
    recombinant dna pcdna3 cmyc addgene addgene - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    Image Search Results


    Figure 3. Cell-cycle arrest and apoptosis induced by the combination treatment (A and B) Flow cytometry analysis of EdU (5-ethynyl-2’-deoxyuridine) and DNA staining. H460 and H1703 cells were treated with vehicle, MYCi975 (5 μM), TMP195 (25 μM), or both for 48 h, then incubated with EdU for 2 h and stained for EdU and FxCycle Violet. Representative flow cytometry dot plots illustrating the gating strategy (A). A, G0/G1; B, S; C, G2/M. Percentages of cells in G0/G1, S, or G2/M phase are presented as mean ± SD (B). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 calculated using one-way ANOVA followed by Tukey’s multiple comparisons test. n = 3 biological replicates. (C) Flow cytometry analysis of phosphatidylinositol (PI) and Annexin V staining. H460 and H1703 cells were treated with vehicle, MYCi975 (5 μM), TMP195 (25 μM), or both for 72 h. Representative flow cytometry dot plots illustrating the gating strategy. A, necrotic; B, late apoptotic; C, early apoptotic. (D) Percentages of cells in necrotic, late-apoptotic, or early-apoptotic status treated with vehicle, MYCi975 (5 μM), TMP195 (25 μM), or both for 24, 48, and 72 h are presented as mean ± SD. n = 3 biological replicates. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 calculated for necrotic + apoptotic cell percentages for each condition using one-way ANOVA followed by Tukey’s multiple comparisons test. V, vehicle; M, MYCi975; T, TMP195; C, combo (B and D).

    Journal: Cell reports

    Article Title: MYC plus class IIa HDAC inhibition drives mitochondrial dysfunction in non-small cell lung cancer.

    doi: 10.1016/j.celrep.2025.115722

    Figure Lengend Snippet: Figure 3. Cell-cycle arrest and apoptosis induced by the combination treatment (A and B) Flow cytometry analysis of EdU (5-ethynyl-2’-deoxyuridine) and DNA staining. H460 and H1703 cells were treated with vehicle, MYCi975 (5 μM), TMP195 (25 μM), or both for 48 h, then incubated with EdU for 2 h and stained for EdU and FxCycle Violet. Representative flow cytometry dot plots illustrating the gating strategy (A). A, G0/G1; B, S; C, G2/M. Percentages of cells in G0/G1, S, or G2/M phase are presented as mean ± SD (B). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 calculated using one-way ANOVA followed by Tukey’s multiple comparisons test. n = 3 biological replicates. (C) Flow cytometry analysis of phosphatidylinositol (PI) and Annexin V staining. H460 and H1703 cells were treated with vehicle, MYCi975 (5 μM), TMP195 (25 μM), or both for 72 h. Representative flow cytometry dot plots illustrating the gating strategy. A, necrotic; B, late apoptotic; C, early apoptotic. (D) Percentages of cells in necrotic, late-apoptotic, or early-apoptotic status treated with vehicle, MYCi975 (5 μM), TMP195 (25 μM), or both for 24, 48, and 72 h are presented as mean ± SD. n = 3 biological replicates. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 calculated for necrotic + apoptotic cell percentages for each condition using one-way ANOVA followed by Tukey’s multiple comparisons test. V, vehicle; M, MYCi975; T, TMP195; C, combo (B and D).

    Article Snippet: Cell viability assay with MYC overexpressing H460 cells pcDNA3-cMYC (Addgene, #16011) was reverse-transfected in H460 cells using Lipofectamine 3000 Transfection Reagent (Invitrogen, #L3000001) following the manufacturer’s protocol.

    Techniques: Flow Cytometry, Staining, Incubation

    Figure 5. Combination treatment induces large-scale changes in chromatin accessibility (A) Volcano plots of ATAC-seq consensus peaks. Orange dots represent DARs with adjusted p <0.05. Each dot represents one peak. H460 cells were treated with vehicle, MYCi975 (5 μM), TMP195 (25 μM), or both for 24 h. n = 4 biological replicates. (B) Heatmaps representing ATAC-seq peaks within DARs (combo vs. vehicle) for indicated samples in H460 cells.

    Journal: Cell reports

    Article Title: MYC plus class IIa HDAC inhibition drives mitochondrial dysfunction in non-small cell lung cancer.

    doi: 10.1016/j.celrep.2025.115722

    Figure Lengend Snippet: Figure 5. Combination treatment induces large-scale changes in chromatin accessibility (A) Volcano plots of ATAC-seq consensus peaks. Orange dots represent DARs with adjusted p <0.05. Each dot represents one peak. H460 cells were treated with vehicle, MYCi975 (5 μM), TMP195 (25 μM), or both for 24 h. n = 4 biological replicates. (B) Heatmaps representing ATAC-seq peaks within DARs (combo vs. vehicle) for indicated samples in H460 cells.

    Article Snippet: Cell viability assay with MYC overexpressing H460 cells pcDNA3-cMYC (Addgene, #16011) was reverse-transfected in H460 cells using Lipofectamine 3000 Transfection Reagent (Invitrogen, #L3000001) following the manufacturer’s protocol.

    Techniques: